DocWire News Editors

DocwireNews

The daily use of colchicine significantly reduces the risk of first and total ischemic cardiovascular (CV) events compared to placebo in patients with a recent myocardial infarction (MI), according to newly presented <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1912388">findings</a> from the American Heart Association 2019 Scientific Sessions in Philadelphia.Researchers enrolled 4,745 participants from 167 sites. The study participants were required to have suffered a heart attack within the last 30 days and have completed any planned percutaneous revascularization procedures. Subjects were randomized (1:1) to receive either 0.5 mg/daily of colchicine or a placebo and were followed until the occurrence of at least 301 CV events. Follow-up visits occurred at one and three months following randomization, and every three months thereafter. Patients also received standard medical care including intensive use of statins. The primary study endpoint was the time from randomization to the first event of CV mortality, resuscitated cardiac arrest, non-fatal MI, non-fatal stroke, or urgent hospitalization for angina requiring coronary revascularization.The results indicated that patients treated with colchicine experienced a 23% lower rate of the composite primary endpoint juxtaposed with patients taking placebo. Moreover, the reduction in risk of the primary endpoint with colchicine was augmented by 28% in patients who adhered to the testing protocol while undergoing at least six months of treatment, with event rates of 5.0% and 6.9% for colchicine and placebo, respectively. Risk reduction for the primary endpoint was achieved in 35% of patients receiving therapy, with event rates of 4% in the colchicine group and 6.1% in the placebo group, respectively. Overall, rate of total primary endpoint events was reduced by 34% with colchicine compared with placebo therapy.&ldquo;The COLCOT results apply to patients who have recently suffered a myocardial infarction,&rdquo; researcher Jean-Claude Tardif, MD, of Montreal Heart Institute said in a presentation. &ldquo;Further research is needed to assess the benefits of colchicine in other high-risk patients.&rdquo;

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

COLCOT: Colchicine Reduces Ischemic Event Risk after Recent MI

AHA 2019

The daily use of colchicine significantly reduces the risk of first and total ischemic cardiovascular (CV) events compared to placebo in patients with a recent myocardial ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe